PPPeerada Pongsakornkullachart

Peerada Pongsakornkullachart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peerada Pongsakornkullachart has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy

    by Peerada Pongsakornkullachart, Pimchanok Kulsirichawaroj, Ratcharin Kongkasuwan, Prakarn Tovichien, Settapong Jitwongwai, Supaluck Kanjanauthai, Nutnicha Preeprem, Sivaporn Limpaninlachat, Nisasri Sermpon, Oranee Sanmaneechai

    Supported by encouraging trial outcomes, onasemnogene abeparvovec (OA) was authorized for spinal muscular atrophy (SMA). Nevertheless, efficacy of OA in advanced SMA patients remains underexplored. This investigation assessed clinical effectiveness and adverse effects of OA in a cohort including advanced SMA, and compared to historical survival data for SMA type 1 patients in Thailand. We conducted observational cohort study at Siriraj Hospital, Thailand, from May 2019 to April 2022. The study enrolled eight SMA patients receiving OA therapy. The cohort comprised five SMA type 1 patients treated at 16.7 months (6.5–24.9 months) and three SMA type 2 patients treated at 20.3 months (19–31.5 months). Before receiving OA, all Type 1 patients required 24-hour invasive ventilation and feeding support. Post-treatment, Three of five showed gradual improvement in motor scores, but none achieved new motor milestones. Survival rate was not improved, with all experiencing fatalities. Conversely, Type 2 patients exhibited motor score improvement without serious adverse events. OA did not significantly improve clinical outcomes or survival rates in advanced Type 1 SMA. These findings highlight need for additional caution when administering OA to severe SMA Type 1 and more specific guidelines in selecting subgroups for treatment.


  • Open Access

    Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy

    by Oranee Sanmaneechai, Peerada Pongsakornkullachart, Pimchanok Kulsirichawaroj, Ratcharin Kongkasuwan, Prakarn Tovichien, Settapong Jitwongwai, Supaluck Kanjanauthai, Nutnicha Preeprem, Sivaporn Limpaninlachart, Nisasri Sermpon

    Objective Supported by encouraging trial outcomes, onasemnogene abeparvovec (OA) was authorized for treating spinal muscular atrophy (SMA) in children under 2 years of age. Nevertheless, the efficacy of OA in advanced SMA patients remains underexplored. This investigation assessed the clinical effectiveness and adverse effects of OA in a patient cohort including those with advanced SMA, and compared these outcomes to historical survival data for SMA type 1 patients in Thailand. Methods We conducted an observational cohort study at Siriraj Hospital, Thailand, from May 2019 to April 2022. The study enrolled eight SMA patients receiving OA therapy. We monitored safety through laboratory tests and clinical evaluations. Patient outcomes, such as motor scores, motor milestones, and survival status, were analyzed. Results The cohort comprised five SMA type 1 patients treated at median age of 16.7 months (6.5–24.9 months) and three SMA type 2 patients treated at median age of 20.3 months (19–31.5 months). Before receiving OA, all type 1 patients needed invasive ventilation and nutritional support by feeding tubes. Posttreatment, these patients did not achieve new motor milestones, their survival rates remained static, and each patient experienced severe adverse events, including fatalities. Conversely, type 2 patients exhibited improved motor scores without experiencing serious adverse events. Interpretation: This real-world evaluation revealed that OA did not significantly improve outcomes or survival rates among advanced SMA type 1 patients, with all such cases resulting in mortality. These findings suggest the need for additional caution and revised guidelines when administering OA to this subgroup.